You are here

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence
Denosumab, cortical bone and bone erosions in rheumatoid arthritis
Free
  1. Maurizio Rossini,
  2. Giovanni Adami,
  3. Ombretta Viapiana,
  4. Luca Idolazzi,
  5. Davide Gatti
  1. Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy
  1. Correspondence to Professor Maurizio Rossini, Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, Verona 37134, Italy; maurizio.rossini{at}univr.it

https://doi.org/10.1136/annrheumdis-2016-210022

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Takeuchi et al1 demonstrate an additional inhibitory effect on the progression of bone erosions in rheumatoid arthritis (RA) with the addition to methotrexate of an anti-receptor activator of nuclear factor kappa-B ligand (RANKL) antibody, denosumab, confirming results already reported 8 years ago by Cohen and colleagues.2 Insufficient inhibition of structural joint damage by disease-modifying antirheumatic drugs (DMARDs) was reported despite clinical improvement,3–5 and recently two meta-analysis6 ,7 showed that methotrexate combined with biologics is statistically superior to methotrexate in inhibiting radiographic progression, but the estimated mean change with all treatments was less than the minimal clinically important difference.

    On the other side, from the bone point of view, we previously observed that low bone mineral density (BMD) at the cortical site was significantly associated with the presence of bone erosions,8 and recently Zhu and colleagues reported alterations in the density and microstructure of the cortical bone of patients with RA, providing new insight into the microstructural basis of bone involvement in RA.9 In particular, in patients with anticitrullinated protein antibodies, cortical thinning might be present even before the clinical onset of RA and it seems strictly related with the risk of bone erosions.10

    Denosumab is a well-known, effective agent for increasing BMD, both at trabecular and cortical sites,11 ,12 and has been showed to prevent metacarpal bone loss in patients with RA,13 and improve cortical porosity.14 An intriguing hypothesis is that the effects of denosumab in terms of prevention of bone erosions are mainly due to its positive effects on cortical BMD and porosity.

    We think that, in the future, treatment with agents not only targeting inflammation but improving cortical bone should deserve more consideration in order to achieve better prevention of bone erosions in RA. Non-responders to the DMARDs in terms of progression of bone erosions could be indeed the consequences of a concomitant osteoporosis. The lack of data about BMD might represent an important bias for meta-analysis on effects of DMARDs on radiographic progression of RA.

    References

    1. ↵
      1. Takeuchi T,
      2. Tanaka Y,
      3. Ishiguro N, et al
      . Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 2016;75:983–90. doi:10.1136/annrheumdis-2015-208052
      OpenUrlAbstract/FREE Full Text
    2. ↵
      1. Cohen SB,
      2. Dore RK,
      3. Lane NE, et al
      . Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299–309. doi:10.1002/art.23417
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      1. Molenaar ETH,
      2. Voskuyl AE,
      3. Dinant HJ, et al
      . Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50:36–42. doi:10.1002/art.11481
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      1. Mulherin D,
      2. Fitzgerald O,
      3. Bresnihan B
      . Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39:115–24. doi:10.1002/art.1780390116
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      1. Rezaei H,
      2. Saevarsdottir S,
      3. Forslind K, et al
      . In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 2012;71:186–91. doi:10.1136/annrheumdis-2011-200038
      OpenUrlAbstract/FREE Full Text
    6. ↵
      1. Singh JA,
      2. Hossain A,
      3. Tanjong Ghogomu E, et al
      . Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev 2016;5:CD012183. doi:10.1002/14651858.CD012183
      OpenUrlPubMed
    7. ↵
      1. Hazlewood GS,
      2. Barnabe C,
      3. Tomlinson G, et al
      . Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 2016;353:i1777. doi:10.1136/bmj.i1777
      OpenUrlAbstract/FREE Full Text
    8. ↵
      1. Rossini M,
      2. Bagnato G,
      3. Frediani B, et al
      . Relationship of focal erosions, bone mineral density, and parathyroid hormone in rheumatoid arthritis. J Rheumatol 2011;38:997–1002. doi:10.3899/jrheum.100829
      OpenUrlAbstract/FREE Full Text
    9. ↵
      1. Zhu TY,
      2. Griffith JF,
      3. Qin L, et al
      . Alterations of bone density, microstructure, and strength of the distal radius in male patients with rheumatoid arthritis: a case-control study with HR-pQCT. J Bone Miner Res 2014;29:2118–29. doi:10.1002/jbmr.2221
      OpenUrlCrossRefPubMed
    10. ↵
      1. Kleyer A,
      2. Finzel S,
      3. Rech J, et al
      . Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 2014;73:854–60. doi:10.1136/annrheumdis-2012-202958
      OpenUrlAbstract/FREE Full Text
    11. ↵
      1. Cummings SR,
      2. San Martin J,
      3. McClung MR, et al
      . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–65. doi:10.1056/NEJMoa0809493
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      1. Seeman E,
      2. Delmas PD,
      3. Hanley DA, et al
      . Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010;25:1886–94. doi:10.1002/jbmr.81
      OpenUrlCrossRefPubMedWeb of Science
    13. ↵
      1. Sharp JT,
      2. Tsuji W,
      3. Ory P, et al
      . Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:537–44. doi:10.1002/acr.20172
    14. ↵
      1. Kostenuik PJ,
      2. Smith SY,
      3. Jolette J, et al
      . Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 2011;49:151–61. doi:10.1016/j.bone.2011.03.769
      OpenUrlCrossRefPubMed
    View Abstract

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles